Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- DYN
- Price
- 15.28
- Stock movement down
- -0.26 (-1.67%)
- Company name
- Dyne Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.52B
- Ent value
- 2.12B
- Price/Sales
- 1600.44
- Price/Book
- 3.64
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 18.56%
- 1 year return (CAGR)
- 8.75%
- 3 year return (CAGR)
- 4.47%
- 5 year return (CAGR)
- -4.75%
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
DYN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1600.44 |
| Price to Book | 3.64 |
| EV to Sales | 1347.04 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 164.65M |
| EPS (TTM) | -2.99 |
| FCF per share (TTM) | -2.80 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.57M |
| Gross profit (TTM) | -216.00K |
| Operating income (TTM) | -449.16M |
| Net income (TTM) | -423.80M |
| EPS (TTM) | -2.99 |
| EPS (1y forward) | -3.32 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -13.74% |
| Operating margin (TTM) | -28572.71% |
| Profit margin (TTM) | -26959.35% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 573.61M |
| Net receivables | 0.00 |
| Total current assets | 806.26M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 53.99M |
| Total assets | 867.06M |
| Accounts payable | 12.06M |
| Short/Current long term debt | 120.47M |
| Total current liabilities | 59.85M |
| Total liabilities | 175.28M |
| Shareholder's equity | 691.78M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -375.71M |
| Capital expenditures (TTM) | 21.30M |
| Free cash flow (TTM) | -397.01M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -61.26% |
| Return on Assets | -48.88% |
| Return on Invested Capital | -53.24% |
| Cash Return on Invested Capital | -49.88% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 15.81 |
| Daily high | 15.81 |
| Daily low | 14.67 |
| Daily Volume | 2.35M |
| All-time high | 47.04 |
| 1y analyst estimate | 39.13 |
| Beta | 1.31 |
| EPS (TTM) | -2.99 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 26 Feb 2026 |
Downside potential
Loading...
Downside potential data
| DYN | S&P500 | |
| Current price drop from All-time high | -67.52% | -1.82% |
| Highest price drop | -85.52% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -49.96% | -10.84% |
| Avg time to new high | 68 days | 12 days |
| Max time to new high | 839 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.52B
Marketcap category
Mid-cap
Description
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Employees
240
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page